In Brief: Biocontrol's Diasensor
This article was originally published in The Gray Sheet
Biocontrol's Diasensor: 510(k) for the noninvasive transcutaneous glucose monitor slated for review by FDA's Clinical Chemistry and Clinical Toxicology Devices Panel at a Feb. 26 meeting at the Gaithersburg Holiday Inn in Gaithersburg, Maryland, according to a Feb. 8 Federal Register notice. Contact FDA's Cornelia Rooks at 301/594-1243 for more information...
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.